Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2454733 | 0.85 | CA12 (0.35) | CA12CA1CA2CA9ESR1 | |
| SCHEMBL9974272 | 0.79 | MPO (0.32) | MPO | |
| SCHEMBL12871797 | 0.79 | POLB (0.33) | MPO | |
| SCHEMBL2765997 | 0.79 | CA12 (0.32) | CA12CA1CA2CA9ESR1 | |
| SCHEMBL23398763 | 0.78 | RET (0.31) | MPO | |
| SCHEMBL23403572 | 0.78 | RET (0.31) | MPO | |
| Butadiene SCHEMBL2766022 | 0.76 | CA12 (0.31) | CA12CA1CA2CA9 | |
| SCHEMBL14401138 | 0.73 | MAP3K12 (0.35) | — | |
| SCHEMBL12871859 | 0.73 | PTGS1 (0.34) | ESR1MPO | |
| SCHEMBL18724843 | 0.72 | HCAR2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374008-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2018133730-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREFOR | 四川科伦博泰生物医药股份有限公司 | 2018-07-26 | — | — | WO | disclosed |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | CA12 4300/4885CA1 3713/4885CA2 690/4885 |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | CA12 762/4885CA1 2205/4885CA2 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.